research use only

Homoharringtonine (HHT) STAT inhibitor

Name: Homoharringtonine (HHT)
Brand: Selleck Chemicals
SKU: S9015
Availability: InStock
Rating: 5 (22 reviews)

Cat.No.S9015

Homoharringtonine (HHT), a plant alkaloid with antitumor properties, inhibits protein translation by preventing the initial elongation step of protein synthesis via an interaction with the ribosomal A-site. This compound reversiblely inhibits IL-6-induced STAT3 Tyrosine 705 phosphorylation and reduced anti-apoptotic proteins expression.

Chemical Structure

Molecular Weight: 545.62

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.81%

99.81

Related Targets	EGFR JAK Pim
Related Products	Stattic NSC 74859 (S3I-201) Cryptotanshinone (Tanshinone C) SH-4-54 C188-9 (TTI-101) BP-1-102 Napabucasin (BBI608) HO-3867 Nifuroxazide AS1517499 STAT5-IN-1 Ochromycinone (STA-21) HJC0152 APTSTAT3-9R STAT3-IN-1 SC-1 Narciclasine SH5-07 (SH-5-07) Scutellarin

Chemical Information, Storage & Stability

Molecular Weight	545.62	Formula	C₂₉H₃₉NO₉	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	26833-87-4	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	CGX-635, Myelostat, NSC 141633			Smiles	CC(C)(CCCC(CC(=O)OC)(C(=O)OC1C2C3=CC4=C(C=C3CCN5C2(CCC5)C=C1OC)OCO4)O)O

Solubility

In vitro
Batch:

DMSO : 100 mg/mL ( (183.27 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 50 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (9.16mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (9.16mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro	Homoharringtonine (HHT), a plant alkaloid with antitumor properties, induces p62-mediated autophagy in resistant CML K562G cells, thus promoting autophagic degradation of the BCR-ABL protein.^[1]
In vivo	In combination with ABT-199, Homoharringtonine (HHT) significantly prolongs overall survival of primary diffuse large B-cell lymphoma (DLBCL) xenograft-bearing mice compared with single-agent approaches.^[2]
References	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908937/ https://pubmed.ncbi.nlm.nih.gov/26467384/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06259292	Recruiting	Hereditary Hemorrhagic Telangiectasia\|Arteriovenous Malformations\|Telangiectasia\|Epistaxis\|GastroIntestinal Bleeding\|Cerebral Arteriovenous Malformations\|Vascular Malformation	Cure HHT\|Augusta University\|The Cleveland Clinic\|Mayo Clinic\|Massachusetts General Hospital\|Columbia University\|Oregon Health and Science University\|University of California Los Angeles\|University of California San Francisco\|University of Colorado Denver\|University of North Carolina Chapel Hill\|University of Pennsylvania\|University of Texas\|University of Utah\|Washington University School of Medicine\|Yale University\|Health Resources and Services Administration (HRSA)\|Children''s Hospital of Philadelphia	November 13 2023	--
NCT05954481	Recruiting	Hereditary Hemorrhagic Telangiectasia\|Rendu Osler Disease	Hospices Civils de Lyon	August 3 2023	Not Applicable
NCT03850964	Recruiting	Hereditary Hemorrhagic Telangiectasia\|Epistaxis\|Anemia\|Nosebleed\|HHT	Cure HHT	May 8 2023	Phase 2\|Phase 3
NCT04976036	Recruiting	Telangiectasia Hereditary Hemorrhagic	Dr. Romain Lazor\|Boehringer Ingelheim\|Centre Hospitalier Universitaire Vaudois	May 5 2022	Phase 2
NCT06266624	Active not recruiting	HHT	University Hospital Essen	September 25 2020	Not Applicable
NCT03910244	Completed	Telangiectasia Hereditary Hemorrhagic	The Cleveland Clinic\|RTI International	October 17 2019	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):